Atlas Trials

Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab in Unresectable Biliary Tract Cancer

Clinical trial NCT04984980 · UNKNOWN

Trial details

NCT number
NCT04984980
Sponsor
Fudan University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Biliary Tract CarcinomaInitially Unresectable
Start date
2020-08-01
Primary completion
2023-07-01
Enrollment
37

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.